Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Binimetinib"

3 News Found

Alembic Pharma receives USFDA tentative approval for Binimetinib tablets
Drug Approval | June 20, 2026

Alembic Pharma receives USFDA tentative approval for Binimetinib tablets

Company becomes sole first applicant for 45 mg strength, positioning itself for potential 180-day generic exclusivity in the US market

Pfizer’s Braftovi+Mektovi shows sustained long-term survival in patients with advanced lung cancer
Clinical Trials | October 22, 2025

Pfizer’s Braftovi+Mektovi shows sustained long-term survival in patients with advanced lung cancer

Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population

Alembic Pharmaceuticals receives 5 USFDA product approvals in Q1 FY25
Drug Approval | May 10, 2024

Alembic Pharmaceuticals receives 5 USFDA product approvals in Q1 FY25

Receives 3 final and 2 tentative product approvals thus far in Q1FY25

Upcoming E-conference
July 17, 2026 Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma

Latest Stories

Zydus’s acquisition of Assertio to bolster its specialty pharma presence in US market

Alembic Pharma receives USFDA tentative approval for Binimetinib tablets

Manipal Hospitals Mukundapur launches advanced Neuro Biplane Cathlab

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics
Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics
Dr. Manjiri Bakre CEO and Founder, OncoStem Diagnostics
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
Akhil Ravi Chief Executive Officer, Aurigene Pharmaceutical Services Limited
Our D2 lamp portfolio caters to entire spectrum of chromatography and spectroscopy customers: Hemang Jhaveri, Partner, Hiten Techno Products Corporation
Our D2 lamp portfolio caters to entire spectrum of chromatography and spectroscopy customers: Hemang Jhaveri, Partner, Hiten Techno Products Corporation

Packaging